Esomeprazole vs Lansoprazole: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Esomeprazole irreversibly inhibits the H+/K+ ATPase proton pump in gastric parietal cells, raising stomach pH from its normal 1.5–3.5 to 4.0–6.0. This acid suppression cripples the absorption of nutrients that require an acidic environment: iron needs acid to convert from Fe³⁺ to absorbable Fe²⁺, calcium carbonate dissolves only below pH 4, B12 must be cleaved from food proteins by pepsin (which requires acid activation), and magnesium and zinc absorption both decline in alkaline conditions. CTD documents only 2 gene interactions for esomeprazole, the narrowest molecular footprint of any PPI.
Esomeprazole achieves 90% oral bioavailability — the highest among PPIs — with a 1.25-hour plasma half-life. Despite the short half-life, its irreversible proton pump binding provides 24+ hours of acid suppression per dose.
- ✓Highest PPI bioavailability (90%) ensures consistent acid suppression and predictable depletion timing
- ✓Only 2 CTD gene interactions — the cleanest molecular profile of any PPI
- ✓FAERS logs 55,842 reports with 10.8% death-associated rate — lower than lansoprazole's 18.6%
- ✓S-enantiomer design provides more predictable CYP2C19 metabolism than racemic omeprazole
- ✗Six-nutrient depletion burden is identical to lansoprazole — no acid-suppression PPI spares these nutrients
- ✗Higher cost than generic lansoprazole adds up over months or years of therapy
- ✗ChEMBL documents 136 RCTs — slightly fewer than lansoprazole's 137, with comparable but not larger evidence base
- ✗CYP2C19 poor metabolizers experience significantly higher drug exposure and potentially deeper acid suppression
Patients who need reliable, predictable acid suppression with minimal drug interaction complexity — especially those already taking multiple CYP-metabolized medications.
Lansoprazole inhibits the same H+/K+ ATPase proton pump through irreversible covalent binding, producing equivalent acid suppression and identical nutrient absorption impairment. However, CTD documents 88 gene interactions for lansoprazole — 44 times more than esomeprazole — spanning inflammatory signaling genes, apoptotic pathways, and drug transporter proteins. This dramatically broader molecular footprint suggests lansoprazole has off-target effects well beyond simple acid suppression that may compound the nutrient depletion burden through additional metabolic interference.
Lansoprazole has 85% oral bioavailability with a 1.0-hour half-life and requires administration 30 minutes before meals for optimal activation in the acidic parietal cell canaliculus.
- ✓Generic availability since 2009 makes it one of the most affordable PPIs for long-term therapy
- ✓ChEMBL documents 137 RCTs across diverse GI conditions including H. pylori eradication
- ✓Available in orally disintegrating tablet form — useful for patients with swallowing difficulties
- ✓88 CTD gene interactions provide the richest pharmacogenomic data for personalized dosing research
- ✗FAERS logs 163,009 adverse event reports — nearly 3x esomeprazole's volume — with 18.6% death-associated rate
- ✗88 CTD gene interactions indicate substantially broader off-target metabolic disruption
- ✗Lower bioavailability (85%) may produce less consistent acid suppression in some patients
- ✗94.8% of FAERS reports classified as serious versus esomeprazole's 92.8%
Cost-conscious patients needing long-term PPI therapy who don't have complex medication regimens and can commit to comprehensive mineral supplementation monitoring.
Feature Comparison
| Feature | Esomeprazole | Lansoprazole |
|---|---|---|
| Drug Class | PPI (S-enantiomer benzimidazole) | PPI (substituted benzimidazole) |
| Nutrients Depleted | 6 — Mg, Ca, Fe, B12, Zn, vitamin C | 6 — Mg, Ca, Fe, B12, Zn, vitamin C |
| CTD Gene Interactions | 2 documented | 88 documented |
| Bioavailability | 90% | 85% |
| Half-Life | 1.25 hours | 1.0 hours |
| FAERS Reports | 55,842 (10.8% death-associated) | 163,009 (18.6% death-associated) |
| FAERS Serious Rate | 92.8% | 94.8% |
| Primary Indications | GERD, erosive esophagitis, Zollinger-Ellison | GERD, duodenal ulcers, H. pylori eradication |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
Both PPIs deplete the same six nutrients through identical proton pump inhibition — your supplementation protocol stays the same regardless of which you take. The differentiators are molecular footprint and safety signal. Esomeprazole's 2 CTD gene interactions versus lansoprazole's 88 indicate a dramatically narrower off-target profile, and FAERS data reinforces this: lansoprazole logs nearly 3x the adverse reports (163,009 vs 55,842) with a higher death-associated rate (18.6% vs 10.8%). Some of that gap reflects lansoprazole's longer generic availability and higher prescribing volume, but the magnitude warrants attention. For patients who can afford it, esomeprazole's cleaner profile and higher bioavailability make it the more precise choice. For cost-sensitive patients, generic lansoprazole delivers equivalent acid suppression at a fraction of the price — just with a broader molecular footprint to monitor.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): 2 gene interactions for esomeprazole, 31 disease associations; 88 gene interactions for lansoprazole, 2,298 disease associations
- [2]ChEMBL bioactivity database: 136 RCTs for esomeprazole; 137 RCTs for lansoprazole across gastroesophageal and ulcer indications
- [3]FAERS (FDA Adverse Event Reporting System): 55,842 esomeprazole reports (10.8% death-associated, 92.8% serious); 163,009 lansoprazole reports (18.6% death-associated, 94.8% serious)
- [4]PharmGKB pharmacogenomics database: CYP2C19 metabolizer status annotations affecting PPI exposure and acid suppression depth for both drugs
- [5]PubMed PMID 26462987 — Cheungpasitporn W et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review. QJM. 2015;108(7):523-530
Check your medications
Check Free →